藏药“帕朱胶囊”中微量元素及重金属元素分析

为探讨藏药“帕朱胶囊”中微量元素与其治疗胃病的相关性,以及监测藏药中的重金属含量,采用原子吸收分光光度法,对帕朱胶囊中的11种元素进行了测定。结果表明,帕朱胶囊中Fe元素含量较高,并含有Cu、Zn、Mn、Se等与治疗胃病直接相关的微量元素,重金属元素Pb、As、Hg含量不超标。为研究传统藏药帕朱胶囊的药效物质基础和安全使用,提供了科学依据。

藏药帕朱胶囊超临界CO_2萃取成分的GC-MS分析

目的:分析治疗胃病常用的藏成药帕朱胶囊(寒水石,诃子,石榴子,胡椒,荜拔等)的主要化学成分。方法:采用超临界CO2萃取方法提取帕朱胶囊的可溶性成分,并用气相色谱-质谱联用法对提取部位进行化学成分分析,峰面积归一化法计算各组分的相对含量。结果:共分离鉴定了22种化合物,主要成分含量为胡椒碱44.2%、亚油酸21.1%、甲基-甲撑基奥-异丙烯内酯10.5%、棕榈酸4.8%和γ-羟基-榄香烯酸内酯3.5%等。结论:藏药帕朱胶囊的主要化学成分为胡椒碱和亚油酸,两者含量共占全部提取物的65.3%

The Exploration of the Clinical Treatment of Chronic Atrophic Gastritis

Purpose:To explore the effect of the clinical treatment of chronic atrophic gastritis Methods:70 patients with chronic atrophic gastritis treated in our hospital from October 2017 to November 2018 were selected and randomly divided into an observation group and a control group with 35 patients in each group.The control group received standard triad treatment with gastroprokinetic drug orally.On the basis of the control group,patients in the observation group received Xianlu Pazhu Wan.The treatment efficiency,eradication rate of helicobacter pylori(H.pylori),incidence of adverse effects and length of stay were compared between the two groups.Results:Compared with the control group,patients in the observation group had higher treatment efficiency,higher H.pylori eradication rate,lower incidence of adverse effects,and shorter length of stay with statistical significance(P<0.05).Conclusion:In the clinical treatment of patients with chronic atrophic gastritis,adding Xianlu Pazhu Wan into the basic medication plan can have better treatment efficiency,reduce the incidence of adverse effects,and shorten the length of stay.Therefore,Xianlu Pazhu Wan should be promoted in the practice.

帕珠丸对急性酒精性肝损伤小鼠解酒保肝作用研究

目的建立小鼠醉酒模型及急性酒精性肝损伤模型,探讨藏药帕珠丸对醉酒小鼠的解酒作用及对急性酒精性肝损伤小鼠的保肝护肝作用的影响。方法抗醉酒研究:采用帕珠丸高中低剂量组进行灌胃干预,以生理盐水作为对照,观测小鼠翻正反射情况、攀附能力。保肝作用研究:正常、模型对照组予生理盐水,联苯双酯组和帕珠丸高中低剂量组予相应剂量药物进行灌胃(15天),末次灌胃后除正常对照组外,其余各组予酒精灌胃制作急性酒精性肝损伤模型,检测其血清AST、ALT、ADH含量及肝脏组织中的MDA、GSH含量。结果与模型组比较,帕珠丸各剂量组可明显延长小鼠翻正反射消失时间并缩短小鼠翻正反射恢复时间(P<0.05),延长小鼠攀附时间(P<0.05)。与正常对照组比,急性酒精肝损伤模型对照组血清ALT、AST、ADH含量及肝组织中MDA均明显升高,肝组织中GSH明显降低(P<0.05)。与模型对照组比,帕珠丸各剂量组可降低血清ALT、AST、ADH及肝组织中的MDA含量,升高肝脏GSH含量(P<0.05)。结论帕珠丸具有较好的防醉、解酒功能,其可能通过降低肝组织MDA、升高GSH含量对急性酒精性肝损伤发挥保肝护肝作用。